Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.64 |
| ▸ | MEN1 | O00255 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.57 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201727 | 0.92 | HTT (0.78) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL4703104 | 0.91 | HTT (0.71) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL4700801 | 0.89 | HTT (0.69) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL1269672 | 0.85 | SMN1; SMN2 (0.82) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL8821050 | 0.84 | HPGD (0.68) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL11590976 | 0.84 | HPGD (0.68) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL77032 | 0.83 | KMT2A (0.68) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL7382460 | 0.81 | HPGD (0.65) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL19372016 | 0.80 | UBE2T (0.70) | HPGDRAB9AHTTSMN1; SMN2ALOX15 | |
| SCHEMBL24198740 | 0.80 | HPGD (0.63) | HPGDRAB9AHTTSMN1; SMN2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | claimed |
| WO-2014067985-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF PARASITIC DISEASES | IRBM SCIENCE PARK S.P.A. (IT) | 2014-05-08 | — | — | WO | disclosed |
| WO-2013138753-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) | 2013-09-19 | — | — | WO | disclosed |
| EP-1363925-B8 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2007-04-25 | — | — | EP | disclosed |
| EP-1363925-B1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060211636-A1 | Macrolide Antibiotics | ALIHODZIC SULEJMAN | 2006-09-21 | — | — | US | disclosed |
| US-20050215495-A1 | Macrolide antibiotics | ALIHODZIC SULEJMAN | 2005-09-29 | — | — | US | disclosed |
| EP-1546116-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040077557-A1 | Macrolide antibiotics | GLAXO GROUP LIMITED (GB) | 2004-04-22 | — | — | US | disclosed |
| WO-2004014871-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363925-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2003-11-26 | — | — | EP | disclosed |
| WO-2002050091-A1 | MACROLIDE ANTIBIOTICS | GLAXO GROUP LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| EP-0161220-B1 | PROCESS FOR THE PREPARATION OF BETA-(BENZOTHIAZOLYLTHIO) AND BETA (BENZIMIDAZOLYLTHIO)CARBOXYLIC-ACID DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-08-14 | — | — | EP | disclosed |
| EP-0161220-A2 | Process for the preparation of beta-(benzothiazolylthio) and beta (benzimidazolylthio)carboxylic-acid derivatives | CIBA-GEIGY AG (CH) | 1985-11-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215495-A1 | Macrolide antibiotics | IL1R1, MRPL12, RPS21 | HPGD 2504/4885RAB9A 1478/4885HTT 3482/4885 |
| US-20060211636-A1 | Macrolide Antibiotics | IL1R1, MRPL12, RPS21 | HPGD 2504/4885RAB9A 1478/4885HTT 3482/4885 |
| US-20040077557-A1 | Macrolide antibiotics | MALT1, MRPL21, IL1R1 | HPGD 2843/4885RAB9A 1258/4885HTT 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.